FBRX · Forte Biosciences, Inc. · Stock research

Current Thesis

The one undated condition flagged in the prior note has cleared. The Hart-Scott-Rodino waiting period expired at 11:59 p.m. ET on 2026-08-18, disclosed in an SC 14D9/A filed 2026-08-19, which states that "the condition set forth in clause (e)(i) of Annex I to the Merger Agreement…has been satisfied." Premerger notification forms were filed 2026-08-03; the period ran its 15 days without a second request. What remains of the $77.00 all-cash tender by Avena Merger Sub — commenced 2026-08-06, expiring one minute after 11:59 p.m. ET on 2026-08-26 — is a single condition: tender of one more share than 50% of shares outstanding. There is no financing condition and no shareholder vote.

The market marked the clearance. The reference close moved from $76.83 on 2026-08-14 to $76.92 on 2026-08-21, narrowing the gross gap to the offer from $0.17 to $0.08, or roughly 0.10%.

The narrative is saturated, and the 2026-08-19 filing dates it. The last genuine piece of uncertainty resolved in the deal's favour and the stock still did not clear the cap — the 52-week high stands at $76.98, two cents under the $77.00 contract. Headline flow ended with the 2026-08-06 commencement release. Coverage is complete, the price is pinned, no competing bid has surfaced.

Bullish and bearish views on Forte Biosciences, Inc.

The model's bull view on Forte Biosciences, Inc. (FBRX), in brief: Antitrust is done. HSR waiting period expired 2026-08-18 at 11:59 p.m. ET with no second request reported (SC 14D9/A, filed 2026-08-19). The regulatory gate that could have pushed this toward the 2026-11-30 outside date is closed. The consideration is fixed and… The bear view: $0.08 of gross gap against a break that reprices in one gap. Both cases follow in full.

Bull Case

• Antitrust is done. HSR waiting period expired 2026-08-18 at 11:59 p.m. ET with no second request reported (SC 14D9/A, filed 2026-08-19). The regulatory gate that could have pushed this toward the 2026-11-30 outside date is closed.
• The consideration is fixed and unfinanced-condition. argenx's 2026-08-06 commencement release states the offer "is not subject to a financing condition," at $77.00 per share "net to the seller in cash, without interest."
• No vote to lose. The two-step structure closes by back-end merger "no later than the first business day following the expiration of the Offer" — the minimum tender substitutes for a shareholder meeting.
• The recommendation has not been withdrawn. The 2026-08-19 amendment reaffirms the offer terms rather than revising the board's position.
• Walking away is expensive for the target. Forte's Q2 2026 10-Q discloses a $65 million termination fee and an outside date of 2026-11-30.

Bear Case

• $0.08 of gross gap against a break that reprices in one gap. The 2026-08-21 close of $76.92 sits 0.10% under the cap. A terminated deal returns the stock toward its pre-announcement level, implied in the mid-$50s by the reported 38.9% premarket gain to $76.10 on 2026-07-27 — inferred from the percentage, not a printed pre-bid close.
• The remaining condition is unobservable until it resolves. Tendered-share counts are not published intraday; the depositary's tally becomes public only in the post-expiration release. Between 2026-08-23 and 2026-08-26 there is no dated datapoint that updates the odds.
• The denominator has a moving part. The Q2 2026 10-Q reports 21,229,087 common shares plus 3,956,842 pre-funded warrants exercisable at nominal cost. How the warrant block is treated for the "one more share than 50% of shares outstanding" test is a mechanical detail of the offer documents, not something resolved by the amendments reviewed here.
• The $77 sell-side target is the contract, not a valuation. Barclays initiated at Overweight with a $74 target on 2026-07-21, then downgraded to Equal-Weight and raised the target to $77 on 2026-07-28 — the number tracks the deal price.
• Success terminates the security. If the offer is accepted for payment, the merger and Nasdaq delisting follow within a business day and the ticker stops trading. There is no post-close instrument.

Setup & Price Structure

• Price: the 2026-08-21 close of $76.92, 0.1% under a 52-week high of $76.98. That high is $0.02 below the offer price; no reported print has cleared $77.00 since the 2026-07-27 announcement.
• The momentum readings are mechanical. RSI(14) at 70.1 and a three-month price change of +256.3% both derive from a single gap — 38.9% premarket to $76.10 on 2026-07-27 — not from expanding participation. Distance above a rising moving average carries no information on a stock pinned inside a sub-1% band by a fixed cash contract.
• Structure: two dated closes are available since commencement, $76.83 (2026-08-14) and $76.92 (2026-08-21). The $0.09 move between them is the entire observable range, and it went the direction HSR clearance implies. Technical levels in the conventional sense do not exist here; the only levels that matter are $77.00 above and the pre-bid zone below.
• Crowding and positioning observables: the Benzinga headline cluster is concentrated on 2026-07-27 (five separate items) with the last piece dated 2026-08-06 — fifteen days of silence into the 2026-08-21 reference close. No earnings date is pending; the Q2 2026 10-Q was filed 2026-08-07. No insider transactions surfaced in the record reviewed for this note. What crowding exists is arbitrage-desk crowding, visible only as the compressed spread itself.

Catalyst Calendar (next 30 days)

• 2026-08-26 — Tender offer and withdrawal rights expire one minute after 11:59 p.m. ET. The only remaining gate resolves here.
• By 9:00 a.m. ET 2026-08-27 — Per the offer terms, any extension must be publicly announced no later than 9:00 a.m. ET on the next business day after the scheduled expiration. Silence at that hour, followed by an acceptance-for-payment release, is the clean outcome.
• ~2026-08-27 (est.) — Back-end merger, payment of $77.00 per share, Nasdaq delisting. Argenx states the merger occurs no later than the first business day after expiration.
• 2026-11-30 (outside the 30-day window) — Outside date under the merger agreement. Only becomes relevant if serial extensions begin.
• 2H 2026 (est.) — FB102 Phase 1b alopecia and Phase 2 celiac topline readouts (Q2 2026 10-Q). Relevant only in a broken-deal scenario, where a standalone Forte would reprice on data instead of on the contract.

What Would Change Our Mind

The structure that would break is the pin. As long as the stock trades within pennies of $77.00, the market is expressing near-certainty that the minimum tender clears. A widening spread is the first observable that consensus has changed, and on a deal with antitrust behind it and no financing condition, a widening spread would have to come from either the tender count or an argenx-side assertion.

Concretely: a daily close below $75 would put the gap at roughly 2.6% into a tender expiring within days, which is not consistent with the conditions disclosed as of 2026-08-19. Beyond price, the 2026-08-26 expiration coming and going with an extension announced — rather than acceptance for payment — would mean the minimum tender failed on the first pass, and every subsequent extension stretches a sub-1% gap toward 2026-11-30. An 8-K disclosing termination, or any argenx statement asserting a material adverse effect, resolves the question immediately and in the other direction.

The reverse also applies: a sustained close above $77.00 would be evidence of something not in the current record — a competing bid or a price bump — since the contract otherwise caps the outcome.

Correlation Notes

• Sector beta is largely switched off. Since 2026-07-26 the payoff has been governed by a fixed cash number, so moves in XBI or the broader clinical-stage biotech complex do not transmit to this price. The residual driver is completion probability.
• argenx's own share price is not a transmission channel. The consideration is all cash with no stock component and no financing condition (2026-08-06 commencement release), so ARGX volatility does not flow through.
• The shared factor with other pending deals is regulatory stance. HSR expiring on 2026-08-18 without a second request on a $2.2 billion pharma acquisition is a datapoint on how small- and mid-cap biotech transactions are being reviewed right now, and it reads across to other announced-but-unclosed biotech tenders more than any FBRX-specific fundamental does.
• Correlation to the FB102 clinical thesis is now zero until proven otherwise. The anti-CD122 asset, its positive Phase 1b celiac and vitiligo results, and the 2H 2026 readouts affect the acquirer's pipeline economics. They only become an FBRX price driver if the deal fails.